Mangalam Drugs & Organics Limited

MANGALAM

INE584F01014

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:54 28/06/2024 pm IST			5-day change	1st Jan Change
104 ^INR	+1.61%		-2.21%	+5.87%

16/03	Mangalam Drugs & Organics Limited agreed to acquire Shri JB Pharma LLP.	CI
13/02	Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Mangalam Drugs & Organics Limited Announces Resignation of Prashant J. Pandit as Independent Director

December 23, 2020 at 09:59 am IST

Mangalam Drugs & Organics Limited announced that the resignation letter received from Shri Prashant J. Pandit affirming that apart from the reason of medical condition as stated in resignation letter, there is no other material reason to resign as Independent Director.

Latest news about Mangalam Drugs & Organics Limited

Mangalam Drugs & Organics Limited agreed to acquire Shri JB Pharma LLP.	16/03	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Half Year Ended September 30, 2023	08/11	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	10/23/10	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Full Year Ended March 31, 2023	30/23/30	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	30/23/30	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/23/13	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	11/22/11	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	05/22/05	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Full Year Ended March 31, 2022	27/22/27	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	26/22/26	CI
Mangalam Drugs & Organics Limited Announces Appointment of Shri Rakesh K. Milwani as an Additional Director (Non- Executive Non- Independent Director)	10/22/10	CI
Mangalam Drugs & Organics Limited Announces Executive Changes	04/22/04	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	04/22/04	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	12/21/12	CI
Mangalam Drugs & Organics Limited Announces Earnings Results for the First Quarter Ended June 30, 2021	12/21/12	CI
Mangalam Drugs & Organics : and Organics Commissions New Manufacturing Facility in Gujarat, India	21/21/21	MT
Mangalam Drugs & Organics Limited Provides Update on Setting-Up of New Intermediate Manufacturing Facility At Unit 1 Located in Vapi, Gujarat	18/21/18	CI
Mangalam Drugs & Organics' : Net Profit Plummets in Fiscal Q4; Shares Plunge 8%	21/21/21	MT
Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	20/21/20	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	11/21/11	CI
Mangalam Drugs & Organics Limited Announces Resignation of Prashant J. Pandit as Independent Director	23/20/23	CI
Mangalam Drugs & Organics Limited Announces Resignation of Prashant J. Pandit, Independent Director	07/20/07	CI
Mangalam Drugs & Organics Limited Announces Change in Directorate	21/20/21	CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	12/20/12	CI

Chart Mangalam Drugs & Organics Limited

Duration

Period

More charts

Company Profile

Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemicals products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed at research and development) is Bictegravir Na (IH).

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MANGALAM DRUGS & ORGANICS LIMITED	+5.87%	19.4M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.76%	43.59B
OTSUKA HOLDINGS CO., LTD.	+28.00%	22.54B
SANDOZ GROUP AG	+20.25%	15.73B
CIPLA LIMITED	+18.82%	14.33B
ZYDUS LIFESCIENCES LIMITED	+55.83%	12.75B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.70%	6.48B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.65%	5.67B